Octreotide acetate administration for malignant bowel obstruction induces severe bradycardia in patients with terminal stage cancer: Two case reports

摘要

Dear Editor:Octreotide acetate has recently been used in the management of malignant bowel obstruction in patients with terminal stage cancer. Bradycardia is a known side effect of octreotide acetate in carcinoid tumor and acromegaly and other clinical settings, but has not been previously reported in a case of terminal stage cancer. Bradycardia by octreotide acetate mostly occurs at the start of therapy. This report presents two rare cases in which bradycardia developed 6 and 12 days after the start of octreotide acetate administration in a patient with terminal stage cancer.